Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.3K
2.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Clinical colorectal cancer·2026
Same author

The distinct roles of <i>Negativicoccus</i> and <i>Fusobacterium</i> in proximal- and late-onset colorectal cancer.

Gut microbes·2026
Same author

Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.

Surgical oncology clinics of North America·2026
Same author

Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.

Therapeutic advances in medical oncology·2026
Same author

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

NPJ precision oncology·2026
Same author

Medical Treatment Options in Colorectal Cancer - Expanding the Evidence.

NEJM evidence·2026

Related Experiment Video

Updated: Mar 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

811

Chemotherapy Maintenance.

Pashtoon Murtaza Kasi1, Axel Grothey

  • 1From the *Hematology/Oncology and †Division of Medical Oncology, Mayo Clinic, Rochester, MN.

Cancer Journal (Sudbury, Mass.)
|June 25, 2016
PubMed
Summary
This summary is machine-generated.

The "Continuum of Care" strategy optimizes metastatic colorectal cancer treatment by balancing prolonged therapy with reduced toxicity. This induction-maintenance approach, exemplified by the CAIRO-3 study, improves patient survival.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Related Experiment Videos

Last Updated: Mar 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

811
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Therapeutics

Background:

  • Metastatic colorectal cancer (mCRC) treatment has evolved towards a "Continuum of Care" strategy.
  • This approach integrates induction and maintenance therapy to optimize palliative care.
  • Improved patient survival necessitates advanced treatment strategies for mCRC.

Purpose of the Study:

  • To explore the induction-maintenance approach in first-line therapy for mCRC.
  • To highlight the role of maintenance chemotherapy in prolonging tumor-directed therapy.
  • To address the need for novel agents and improved clinical trial designs in mCRC management.

Main Methods:

  • Review of the "Continuum of Care" concept in mCRC treatment.
  • Discussion of the induction-maintenance approach in first-line therapy.
  • Reference to the CAIRO-3 study as an illustration of maintenance chemotherapy principles.

Main Results:

  • The induction-maintenance approach aims to extend tumor-directed therapy duration.
  • Maintenance chemotherapy utilizes less toxic regimens after initial treatment.
  • The CAIRO-3 study exemplifies the application of maintenance chemotherapy principles.

Conclusions:

  • The "Continuum of Care" represents a paradigm shift in mCRC palliative therapy.
  • Maintenance chemotherapy is crucial for managing long-term mCRC survival.
  • Further research using novel agents and efficient trial designs is essential for mCRC treatment advancement.